Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · GRANTS PASS, OR · NPI 1679534002
Verified facts
CMS Open Payments records show Andrew Pitzak, DO received $25.20 in general payments during 2025 across 1 reported records.
Tactile Systems Technology Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $25.20 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $25.20 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $25.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 121 |
| Losartan Potassium | Losartan Potassium | 284 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 69 |
| Gabapentin | Gabapentin | 203 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 71 |
| Lisinopril | Lisinopril | 177 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 60 |
| Furosemide | Furosemide | 168 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 46 |
| Carvedilol | Carvedilol | 161 | 51 |
| Omeprazole | Omeprazole | 156 | 53 |
| Metformin Hcl | Metformin Hcl | 130 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 42 |
| Trazodone Hcl | Trazodone Hcl | 119 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 34 |
| Potassium Chloride | Potassium Chloride | 109 | 37 |
| Simvastatin | Simvastatin | 107 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 22 |
| Meloxicam | Meloxicam | 96 | 29 |
| Sertraline Hcl | Sertraline Hcl | 96 | 29 |
| Eliquis | Apixaban | 80 | 25 |
| Metformin Hcl Er | Metformin Hcl | 74 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 26 |
| Warfarin Sodium | Warfarin Sodium | 73 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 28 |
| Xarelto | Rivaroxaban | 69 | 16 |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 68 | 67 |
| Tramadol Hcl | Tramadol Hcl | 68 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 21 |
| Prednisone | Prednisone | 60 | 25 |
| Alendronate Sodium | Alendronate Sodium | 57 | 17 |
| Alprazolam | Alprazolam | 56 | 15 |
| Allopurinol | Allopurinol | 53 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 21 |
| Atenolol | Atenolol | 50 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Baclofen | Baclofen | 47 | 13 |
| Spironolactone | Spironolactone | 47 | 16 |
| Celecoxib | Celecoxib | 45 | 15 |
| Finasteride | Finasteride | 43 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Temazepam | Temazepam | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Estradiol | Estradiol | 36 | 14 |
| Lovastatin | Lovastatin | 36 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Jardiance | Empagliflozin | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | 13 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 17 |
| Glipizide | Glipizide | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25.20 · 1 records | Tactile Systems Technology Inc | Flexitouch Plus, Nimbl | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error